Kathryn M. Kinross

Clayton, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Journal: The Journal of clinical investigation

Published: December 15, 2023

Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.

Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.

Journal: Nature medicine

Published: October 24, 2023

A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma.

A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma.

Journal: Neuro-oncology advances

Published: June 08, 2023

Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors: The AIM BRAIN Project: An Australian and New Zealand Children's Haematology/Oncology Group Study.

Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors: The AIM BRAIN Project: An Australian and New Zealand Children's Haematology/Oncology Group Study.

Journal: The Journal of molecular diagnostics : JMD

Published: December 14, 2022

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.

Journal: Nature medicine

Published: August 04, 2022

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Journal: The Journal of clinical investigation

Published: November 24, 2015

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Journal: Cancer discovery

Published: January 29, 2014

Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.

Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.

Journal: The Biochemical journal

Published: December 11, 2013

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 09, 2013

The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.

The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.

Journal: Cancer discovery

Published: December 18, 2012

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Journal: The Journal of clinical investigation

Published: August 09, 2012

Targeting PI3 kinase/AKT/mTOR signaling in cancer.

Targeting PI3 kinase/AKT/mTOR signaling in cancer.

Journal: Critical reviews in oncogenesis

Published: April 05, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026